Safety evaluation of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer

(EUDRACT Number 2017- 004540-37): MITOBCG preliminary results

De Nunzio C. 1, Nacchia A. 1, Lombardo R2, Simone G. 2, Leonardo C. 3, Pastore A. 3, Tubaro A. 1

1Sapienza University of Rome, Sant’Andrea Hospital, Dept. of Urology, Rome, Italy,
2IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy,
3Sapienza University of Rome, Umberto I Hospital, Dept. of Urology, Rome, Italy
4Department of Urology, ICOT Latina, Italy

OBJECTIVE
✓ To evaluate efficacy and safety of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer

MATERIAL & METHODS

Inclusion Criteria
• Patients with high risk non muscle invasive bladder cancer
• High risk of recurrence (EORTC risk score ≥ 10)
• Males
• Signature of Informed Consent
• Ability of consent

Exclusion Criteria
• Low Risk Non-Muscle Invasive Bladder Cancer
• Muscle Invasive Bladder Cancer
• Concomitant Urothelial Bladder Cancer in the Upper-Uriitary Tract
• Previous bladder or prostate surgery
• Prostate or bladder radiotherapy
• Urinary tract infection
• Chronic urinary retention or indwelling catheters
• Neurological patients
• Previous BCG infections
• Previous or current chemotherapy for other kind of cancers
• Patients older than 75
• WHO performance status 3-4
• Residual tumour on re-TURB

Conclusions
• Protocol study started on March 2019
• Enrollment will continue till 200 patients are included
• Preliminary results of our experience (MITOBCG study) support that sequential combination therapy with Mitomycin and BCG is a safety treatment in high risk non muscle invasive bladder cancer.

References